Cardiovascular toxicity by anticancer therapy (chemotherapy, radiotherapy, targeted agents): Utility of early diagnosis and extended cardiological follow up

12^th World Cancer Conference

September 26-28, 2016 London, UK

Fabio Maramao

Regina Elena National Cancer Institute, Italy

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Anticancer treatment with chemotherapy, radiotherapy and targeted agents can lead to heart damages. Cardiotoxicity has a serious clinical and prognostic impact on cancer patients, and early identification is essential in order to start preventative therapy and cardiac support. The conventional tools currently being used for the diagnosis of cardiotoxicity (ECG and conventional echocardiographic study) do not permit early diagnosis of cardiotoxicity. The early diagnosis of cardiotoxicity induced by anticancer therapies is possible with a new approach based on the use of cardiac biomarkers, in particular troponins and with advanced echocardiography. In cancer patients, we can observe radiotherapy and chemotherapy heart damages even after many years. Cancer patient is a chronic patient and frequently requires prolonged, repeated anticancer therapies and repeated interventions of oncologic surgery during the course of his disease. The perioperative cardiologic management it can determine changes that can take time, the consequent delay of the planned surgery to allow the assessment and significant changes in cardiologic management, will negatively affect outcome also with a negative impact on the costs for the time extension of the hospitalization. In cancer patients, we recommend the cardiologic surveillance, also for several years, after radiotherapy and chemotherapy to detect and treat in time heart damages to avoid delays in case of future oncologic timesensitive surgery.

Biography :

Email: maramao@ifo.it